Discontinued — last reported Q1 '18
Consolidated Edison Allowance for Doubtful Accounts Receivable (Current) decreased by 7.7% to $468.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 24.0%, from $616.00M to $468.00M. Over 5 years (FY 2020 to FY 2025), Allowance for Doubtful Accounts Receivable (Current) shows an upward trend with a 27.9% CAGR. This is a positive signal — lower values indicate better performance for this metric.
A significant increase relative to receivables may signal deteriorating customer credit quality or economic headwinds in specific markets.
This is a contra-asset account representing the estimated amount of accounts receivable that the company expects will no...
Standard across all industries; peers in the medical device sector typically maintain low levels unless operating in high-risk emerging markets.
allowance_for_doubtful_accounts_receivable_current| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $275.00M | $313.00M | $317.00M | $336.00M | $336.00M | $305.00M | $322.00M | $244.00M | $275.00M | $276.00M | $360.00M | $394.00M | $434.00M | $461.00M | $620.00M | $616.00M | $615.00M | $610.00M | $507.00M | $468.00M |
| QoQ Change | — | +13.8% | +1.3% | +6.0% | +0.0% | -9.2% | +5.6% | -24.2% | +12.7% | +0.4% | +30.4% | +9.4% | +10.2% | +6.2% | +34.5% | -0.6% | -0.2% | -0.8% | -16.9% | -7.7% |
| YoY Change | — | — | — | — | +22.2% | -2.6% | +1.6% | -27.4% | -18.2% | -9.5% | +11.8% | +61.5% | +57.8% | +67.0% | +72.2% | +56.3% | +41.7% | +32.3% | -18.2% | -24.0% |